# Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines

> **NCT05067946** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Genexine, Inc.**

## Conditions studied

- SARS-CoV2 Infection

## Interventions

- **BIOLOGICAL:** GX-19N
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05067946
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10
- **Primary completion:** 2022-10
- **Final completion:** 2023-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Change of development strategy in consideration of the global COVID-19 situation
- **Last updated:** 2022-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05067946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05067946, "Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05067946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*